Is zanidatamab-hrii for injection - Ziihera on the market?

Zenidatamab for injection (zanidatamab-hrii), brand name Ziihera, has received accelerated approval from the U.S. Food and Drug Administration (FDA) in November 2024. It is mainly used to treat HER2-positive unresectable or metastatic biliary tract cancer. This drug is a bispecific antibody that can simultaneously target two non-overlapping sites on the HER2 receptor and has unique mechanisms and advantages. HER2 is an oncogenic protein highly expressed in a variety of cancers and is closely related to the occurrence and development of tumors.

The approval of zenidatumab for injection is based on positive results from the HERIZON-BTC-01 clinical trial, which demonstrated an objective response rate (ORR) of 52% and a median duration of response (DOR) of 14.9 months. This result demonstrates that injectable zenidatumumab has significant clinical benefit in patients with previously treated HER2-positive biliary tract cancer. The FDA's accelerated approval means this treatment can be brought to market more quickly to meet an unmet medical need, but subsequent extensive research will determine its effectiveness and safety for continued use.

As a targeted therapy, zenidatumab is different from traditional chemotherapy in that it is administered intravenously every two weeks. This dosing frequency provides patient convenience and may also reduce some of the side effects of traditional chemotherapy. Zenidatuzumab binds to the two extracellular sites of the HER2 receptor, promoting the reduction of receptors on the surface of tumor cells, thereby triggering a series of immune responses, including complement-dependent cytotoxicity, antibody-dependent cytotoxicity and antibody-dependent phagocytosis, ultimately achieving the effect of inhibiting tumor growth and inducing tumor cell death.

Overall, the launch of zenidatuzumab for injection brings new hope to patients with HER2-positive biliary tract cancer and marks the further development of medicine in the field of cancer treatment.

Reference materials:https://www.drugs.com/ziihera.html